Hydrocodone bitartrate for chronic pain

Hydrocodone bitartrate is the most commonly used drug for acute and chronic pain in the U.S. with over 135 million prescriptions in 2012. The U.S. is the primary consumer of hydrocodone, using 99% of the global supply for 4.4% of the global population. With its easy availability and abuse patterns,...

Full description

Saved in:
Bibliographic Details
Published inDrugs of today (Barcelona, Spain : 1998) Vol. 51; no. 7; p. 415
Main Authors Manchikanti, L, Atluri, S, Kaye, A M, Kaye, A D
Format Journal Article
LanguageEnglish
Published Spain 01.07.2015
Subjects
Analgesics, Opioid - therapeutic use
Chronic Pain - drug therapy
Drug Interactions
Humans
Hydrocodone - adverse effects
Hydrocodone - pharmacokinetics
Hydrocodone - therapeutic use
Misuse
Abuse
Addiction
Acetaminophen
Hydrocodone
Opioids
Online AccessGet more information

Cover

More Information
Summary:Hydrocodone bitartrate is the most commonly used drug for acute and chronic pain in the U.S. with over 135 million prescriptions in 2012. The U.S. is the primary consumer of hydrocodone, using 99% of the global supply for 4.4% of the global population. With its easy availability and abuse patterns, hydrocodone has been touted as a primary driver of opioid-related abuse and misuse. There are no clinical efficacy studies of hydrocodone in short-acting form in combination with acetaminophen or ibuprofen in chronic pain. Hydrocodone has been approved with two long-term formulations since 2014. The FDA has rescheduled hydrocodone from Schedule III to Schedule II which went into effect on October 6, 2014, along with a limit on added acetaminophen of 325 mg for each dose of hydrocodone. This review examines the evolution of hydrocodone into a common and yet controversial drug in the U.S. with its pharmacokinetics, pharmacodynamics, safety and efficacy.
ISSN:1699-3993
DOI:10.1358/dot.2015.51.7.2361328